These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17075317)

  • 1. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
    Pourpak A; Meyers RO; Samulitis BK; Sherry Chow HH; Kepler CY; Raymond MA; Hersh E; Dorr RT
    Anticancer Drugs; 2006 Nov; 17(10):1179-84. PubMed ID: 17075317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of imexon in patients with advanced malignancy.
    Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
    J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
    Moehler TM; Feneberg R; Ho AD; Golenkov AK; Ludwig H; Kropff M; Khuageva NK; Hajda J; von Broen I; Goldschmidt H
    Anticancer Drugs; 2010 Aug; 21(7):708-15. PubMed ID: 20571355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
    Samulitis BK; Dorr RT; Chow HH
    Anticancer Res; 2011 Sep; 31(9):2781-5. PubMed ID: 21868520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.
    Cho H; Koto M; Riesterer O; Molkentine DP; Giri U; Milas L; Story MD; Ha CS; Raju U
    Anticancer Res; 2009 Nov; 29(11):4409-15. PubMed ID: 20032386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics and antitumor activity of imexon.
    Dorr RT; Liddil JD; Klein MK; Hersh EM
    Invest New Drugs; 1995; 13(2):113-6. PubMed ID: 8617572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
    Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pediatric preclinical testing program: description of models and early testing results.
    Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
    Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
    Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
    Dorr RT; Wisner L; Samulitis BK; Landowski TH; Remers WA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1039-49. PubMed ID: 22186884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
    Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
    Chun AW; Cosenza SC; Taft DR; Maniar M
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.
    Gourdeau H; McAlpine JB; Ranger M; Simard B; Berger F; Beaudry F; Farnet CM; Falardeau P
    Cancer Chemother Pharmacol; 2008 May; 61(6):911-21. PubMed ID: 17622531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.